Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2014 Nov;96(5):572-9. doi: 10.1038/clpt.2014.153. Epub 2014 Aug 8.

Optimizing dosing of oncology drugs.

Author information

1
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
2
Millennium: The Takeda Oncology Company, Cambridge, Massachusetts, USA.
3
Multiple Myeloma Research Foundation, Norwalk, Connecticut, USA.
4
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
5
American Society of Clinical Oncology, Alexandria, Virginia, USA.

Abstract

The purpose of this article is to acknowledge the challenges in optimizing the dosing of oncology drugs and to propose potential approaches to address these challenges in order to optimize effectiveness, minimize toxicity, and promote adherence in patients. These approaches could provide better opportunities to understand the sources of variability in drug exposure and clinical outcomes during the development and premarketing evaluation of investigational new drugs.

PMID:
25105705
DOI:
10.1038/clpt.2014.153
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center